Search results for "severity"

showing 10 items of 1287 documents

Multiple sclerosis severity score: Using disability and disease duration to rate disease severity

2005

Background: There is no consensus method for determining progression of disability in patients with multiple sclerosis (MS) when each patient has had only a single assessment in the course of the disease. Methods: Using data from two large longitudinal databases, the authors tested whether cross-sectional disability assessments are representative of disease severity as a whole. An algorithm, the Multiple Sclerosis Severity Score (MSSS), which relates scores on the Expanded Disability Status Scale (EDSS) to the distribution of disability in patients with comparable disease durations, was devised and then applied to a collection of 9,892 patients from 11 countries to create the Global MSSS. I…

AdultMalemedicine.medical_specialtyMultiple SclerosisDatabases FactualCross-sectional studyModels NeurologicalDiseaseSUSCEPTIBILITYSeverity of Illness IndexCohort StudiesDisability EvaluationPredictive Value of TestsRecurrenceSeverity of illnessmedicineHumansLongitudinal StudiesAge of OnsetModels StatisticalExpanded Disability Status Scalebusiness.industryMultiple sclerosisOUTCOME MEASUREReproducibility of ResultsNATURAL-HISTORYMiddle AgedPrognosismedicine.diseaseCross-Sectional StudiesPredictive value of testsDisease ProgressionPhysical therapyFemaleFranceNeurology (clinical)Age of onsetbusinessCohort study
researchProduct

Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.

2009

Background: There are a few and conflicting results from randomised controlled trials (RCTs) pertaining to the influence of gender in response to currently used disease modifying drugs in Multiple Sclerosis (MS). Observational studies may be especially valuable for answering effectiveness questions in subgroups not studied in RCTs. Objective: To conduct a post-marketing analysis aimed to evaluate the gender effect on Interferon beta (IFN beta) treatment response in a cohort of relapsing (RR) MS patients. Methods: A cohort of 2570 IFN beta-treated RRMS was prospectively followed for Lip to 7 years in 15 Italian MS Centers. Cox proportional hazards regression models were used to assess gender…

AdultMalemedicine.medical_specialtyMultiple SclerosisPropensity scoreDiseasegender; interferon beta; multiple sclerosis; observational study; propensity scoreLower riskSeverity of Illness IndexMultiple sclerosis Interferon beta Gender Observational study Propensity scoreCohort StudiesDisability EvaluationYoung AdultSex Factorsgender multiple sclerosis treatment interferonDouble-Blind MethodInternal medicineObservational studymedicinegenderConfidence IntervalsOdds RatioProduct Surveillance PostmarketingHumansImmunologic FactorsMultiple sclerosiProportional Hazards ModelsExpanded Disability Status ScaleProportional hazards modelbusiness.industryMultiple sclerosisDrug Administration RoutesInterferon-betamedicine.diseaseInterferon betaSurgeryNeurologyItalyCohortPropensity score matchingRegression AnalysisSettore MED/26 - NeurologiaObservational studyFemaleNeurology (clinical)business
researchProduct

Association of reduced glyoxalase 1 activity and painful peripheral diabetic neuropathy in type 1 and 2 diabetes mellitus patients

2013

Abstract Aims The present study was undertaken to investigate the relationship between glyoxalase 1 (Glo1) enzyme activity and painful diabetic neuropathy (DN) in patients with diabetes mellitus. Methods Glo1 activity and biochemical markers were determined in blood samples from 108 patients with type 1 diabetes, 109 patients with type 2 diabetes, and 132 individuals without diabetes as a control. Painful and painless peripheral DN was assessed and multivariate regression analysis was used to determine independent association of Glo1 activity with occurrence of painful DN. Results In patients with type 1 and type 2 diabetes mellitus and painful DN compared to patients with painless DN, Glo1…

AdultMalemedicine.medical_specialtyMultivariate analysisEndocrinology Diabetes and MetabolismPainType 2 diabetesSeverity of Illness IndexGastroenterologyEndocrinologyDiabetic NeuropathiesInternal medicineDiabetes mellitusInternal MedicinemedicineHumansPain MeasurementGlycated HemoglobinType 1 diabetesbusiness.industryConfoundingLactoylglutathione LyasePeripheral Nervous System DiseasesType 2 Diabetes MellitusMiddle Agedmedicine.diseasePeripheralDiabetes Mellitus Type 1EndocrinologyDiabetes Mellitus Type 2Painful diabetic neuropathyDisease ProgressionFemalebusinessBiomarkersJournal of Diabetes and its Complications
researchProduct

Sexual Quality of Life in Patients with Axial Spondyloarthritis in the Biologic Treatment Era.

2019

Author's accepted manuscript. This is a pre-copyediting, author-produced PDF of an article accepted for publication in The Journal of Rheumatology following peer review. The definitive publisher-authenticated version Berg, K. H., Rohde, G., Prøven, A., Benestad, E. E. P., Østensen, M. & Haugeberg, G. (2019). Sexual Quality of Life in Patients with Axial Spondyloarthritis in the Biologic Treatment Era. The Journal of Rheumatology, 46(9), 1075-1083 is available online at: https://www.jrheum.org/content/46/9/1075. Objective. To examine the relationship between demographics, disease-related variables, treatment, and sexual quality of life (SQOL) in men and women with axial spondyloarthritis (ax…

AdultMalemedicine.medical_specialtyMultivariate analysisSexual BehaviorImmunologyDiseasePersonal SatisfactionSeverity of Illness IndexBody Mass Index03 medical and health sciences0302 clinical medicineSex FactorsRheumatologyQuality of lifeInternal medicineSurveys and QuestionnairesSpondylarthritisImmunology and AllergyMedicineOutpatient clinicHumans030212 general & internal medicineAxial spondyloarthritisBASDAI030203 arthritis & rheumatologyBiological Productsbusiness.industryMiddle AgedRheumatologyVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Reumatologi: 759Antirheumatic AgentsQuality of LifeFemalebusinessBASFIThe Journal of rheumatology
researchProduct

Quality of life, needs, and interest among cocaine users: differences by cocaine use intensity and lifetime severity of addiction to cocaine.

2010

We examined the quality of life (QoL) of 149 patients who were recruited in 2005 at outpatient treatment centers for cocaine dependence in Spain. Important life areas and life areas with potential need and interest to change in order to improve the QoL were analyzed in terms of patients? cocaine use intensity within the previous six months and lifetime severity addiction to cocaine. The Spanish versions of the Drug User Quality of Life Scale and the Lifetime Severity Index for Cocaine were used to measure QoL, needs and interest, and severity addiction to cocaine. The data analysis employed t-tests, linear regression, Mann?Whitney U tests, multivariate regression, and chi-square tests. Tail…

AdultMalemedicine.medical_specialtyMultivariate statisticsHealth (social science)Adolescentmedia_common.quotation_subjectEthnic groupMedicine (miscellaneous)Severity of Illness IndexCocaine dependenceDrug userCocaine-Related DisordersCocaine usersQuality of lifeCocaineOutpatientsmedicineHumansPsychiatrymedia_commonHealth Services Needs and DemandAddictionPublic Health Environmental and Occupational HealthMiddle Agedmedicine.diseaseBehavior AddictivePsychiatry and Mental healthPatient SatisfactionNeeds assessmentLinear ModelsQuality of LifeFemalePsychologyNeeds AssessmentClinical psychologySubstance usemisuse
researchProduct

Mirtazapine compared with paroxetine in major depression.

2000

Background: The aim was to compare the efficacy and tolerability of mirtazapine with those of paroxetine. Method: 275 outpatients with a diagnosis of major depressive episode (DSM-IV) and a score ≥ 18 on the 17-item Hamilton Rating Scale for Depression (HAM-D-17) were randomly assigned to 6 weeks of treatment with mirtazapine (15-45 mg/day) or paroxetine (20-40 mg/day). Efficacy was assessed by the HAM-D-17, Hamilton Rating Scale for Anxiety (HAM-A), and Clinical Global Impressions scales (Severity and Improvement), and analyses were performed on the intent-to-treat sample (127 mirtazapine-treated patients and 123 paroxetine-treated patients). Results: Mean daily doses were 32.7 mg of mirta…

AdultMalemedicine.medical_specialtyNauseaMirtazapineMirtazapineMianserinAntidepressive Agents TricyclicSeverity of Illness IndexDrug Administration Schedulelaw.inventionRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineAmbulatory CareHumansPsychiatryMajor depressive episodeAgedPsychiatric Status Rating ScalesDepressive DisorderHamilton Rating Scale for DepressionMiddle AgedParoxetinePsychiatry and Mental healthParoxetineTreatment OutcomeTolerabilityAnxietyFemalemedicine.symptomPsychologymedicine.drugThe Journal of clinical psychiatry
researchProduct

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

2010

On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal antibody rituximab to first-line chemotherapy with fludarabine and cyclophosphamide would improve the outcome of patients with chronic lymphocytic leukaemia.Treatment-naive, physically fit patients (aged 30-81 years) with CD20-positive chronic lymphocytic leukaemia were randomly assigned in a one-to-one ratio to receive six courses of intravenous fludarabine (25 mg/m(2) per day) and cyclophosphamide (250 mg/m(2) per day) for the first 3 days of each 28-day treatment course with or without rituximab (375 mg/m(2) on day 0 of first course, and 500 mg/m(2) on da…

AdultMalemedicine.medical_specialtyNeutropeniaFCR RegimenKaplan-Meier EstimateOfatumumabSeverity of Illness IndexGastroenterologyDisease-Free SurvivalDrug Administration ScheduleAntibodies Monoclonal Murine-Derivedchemistry.chemical_compoundChemoimmunotherapyObinutuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansImmunologic FactorsMedicineCyclophosphamideAgedAged 80 and overbusiness.industryIncidenceAntibodies MonoclonalLeukopeniaGeneral MedicineMiddle AgedLeukemia Lymphocytic Chronic B-CellSurgeryFludarabineTreatment OutcomechemistryDisease ProgressionFemaleRituximabRefractory Chronic Lymphocytic LeukemiaRituximabbusinessVidarabineUntreated Chronic Lymphocytic Leukemiamedicine.drug
researchProduct

Soluble tumor necrosis factor receptor type II in the early diagnosis of fever in neutropenia.

2002

Sepsis in chemotherapy-associated neutropenia is a major cause of mortality in the treatment of acute myeloid leukemia (AML). Early diagnosis of sepsis is crucial for patient survival. We analyzed the value of prospectively measuring serum concentrations of soluble tumor necrosis factor receptor type II (sTNF-RII) in patients with AML for early diagnosis of sepsis in neutropenia. Therefore, 54 adult patients with AML and neutropenia were followed around the onset of fever. A total of 59 febrile episodes were documented. We could not demonstrate a significant increase in sTNF-RII levels prior to fever. sTNF-RII concentrations were not predictive of the severity of a febrile episode. Based on…

AdultMalemedicine.medical_specialtyNeutropeniaTime FactorsFevermedicine.medical_treatmentPilot ProjectsNeutropeniaInfectionsGastroenterologySeverity of Illness IndexReceptors Tumor Necrosis FactorSepsisAntigens CDhemic and lymphatic diseasesInternal medicinemedicineHumansReceptors Tumor Necrosis Factor Type IIProspective StudiesAgedChemotherapyHematologyLeukopeniabusiness.industryOsmolar ConcentrationMyeloid leukemiaHematologyGeneral MedicineMiddle Agedmedicine.diseaseSolubilityLeukemia MyeloidImmunologyAcute DiseaseTumor necrosis factor alphaFemalemedicine.symptombusinessComplicationAnnals of hematology
researchProduct

Multidimensional assessment of OCD: integration and revision of the Vancouver Obsessional-Compulsive Inventory and the Symmetry Ordering and Arrangin…

2010

This article reports on the integration and revision of two self-report measures of obsessive-compulsive symptoms based on data from an obsessive-compulsive disorder (OCD) sample (n=228): the Vancouver Obsessional-Compulsive Inventory (VOCI) and the Symmetry Ordering and Arranging Questionnaire (SOAQ). The revised measure provides scores on five symptom subscales (Contamination, Checking, Hoarding, Symmetry and Ordering, Obsessions). It shows improvement upon current versions in several ways: it has a good model fit, eliminates redundancy, reduces overlap across subscales, is much shorter, and covers those OCD dimensions most frequently identified in factor-analytic studies. Strengths of th…

AdultMalemedicine.medical_specialtyObsessive-Compulsive DisorderPsychometricsTest validityAmbulatory Care FacilitiesPersonality DisordersSeverity of Illness IndexArts and Humanities (miscellaneous)Surveys and QuestionnairesmedicineHumansPsychiatryReferral and ConsultationDepressive DisorderDiscriminant validityConstruct validitymedicine.diseaseAnxiety DisordersPsychophysiologic DisordersClinical PsychologyConvergent validityAnxietyOptimal distinctiveness theoryFemalemedicine.symptomPsychologyAnxiety disorderClinical psychologyJournal of clinical psychology
researchProduct

Olecranon fractures in adults: factors influencing outcome.

2003

In a retrospective, non-randomized study, we reviewed our experience with the operative treatment of olecranon fractures to find out which factors correlate with subjective complaints and functional outcome. A total of 95 consecutive olecranon fractures were operatively treated in our level I trauma institution between 1 March 1992 and 1 March 2000. Medical records and X-rays of all patients were evaluated. Three patients died, 23 were lost to follow-up. Fifty-eight of 69 available patients (84.0%) were reviewed clinically and/or radiologically after a mean time of 36 months. Fracture type, fracture classification, associated lesions, technical correctness of osteosynthesis, age and comorbi…

AdultMalemedicine.medical_specialtyOlecranonElbowFracture Fixation InternalInjury Severity ScoreFracture fixationElbow JointmedicineHumansRange of Motion ArticularGeneral Environmental ScienceAgedRetrospective StudiesAged 80 and overOsteosynthesisbusiness.industryRetrospective cohort studyRecovery of FunctionMiddle Agedmedicine.diseasePrognosisUlna FracturesSurgeryRadiographymedicine.anatomical_structureTreatment OutcomeOlecranon fractureGeneral Earth and Planetary SciencesInjury Severity ScoreFemaleRange of motionbusinessElbow InjuriesBone WiresFollow-Up StudiesInjury
researchProduct